Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Merck
McKinsey
Express Scripts

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 9,895,380

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,895,380
Title:Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
Inventor(s): Andre; Patrice (Lyons, FR), Lotteau; Vincent (Lyons, FR), Radreau; Pauline (Lyons, FR), Gilardone; Marine (Millery, FR), Patin; Amaury (Lausanne, CH), Roche; Didier (Ecully, FR), Cravo; Daniel (Montesson, FR), Hallakou-Bozec; Sophie (Antony, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) EDELRIS (Lyons, FR) POXEL (Lyons, FR)
Application Number:14/917,958
Patent Claims:see list of patent claims

Details for Patent 9,895,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Pa 2033-09-11 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Pa 2033-09-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
McKinsey
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.